Keltjens to step in at JenaValve as Drachman departs
This article was originally published in Clinica
David Drachman has resigned as CEO of German transcatheter aortic valve developer JenaValve after six months, and will be replaced by industry veteran and board chair Jan Keltjens on an interim basis. The company did not say exactly why Mr Drachman decided to leave the company, but that it was due to “non-business-related personal reasons.” He joined the firm in July 2014. Mr Keltjens will take up the reins immediately, until a permanent replacement for Mr Drachman is found. Mr Keltjens joined JenaValve’s board in April and became chair in October. He was most recently CEO of Sapiens Steering Brain Simulation, which was acquired by Medtronic last year. JenaValve already markets its CE-marked transapical TAVI device in Europe and “other markets worldwide”; it plans to CE mark and launch its transfemoral device in Europe in 2016.